BRIEF—Novartis expands US radioligand therapy manufacturing

Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation.

Construction has started at a site in Indianapolis , which will produce radioisotopes needed for RLTs. Another site is being established in Carlsbad, California,.

RLTs combine a tumor-targeting molecule with a radioisotope, allowing radiation to target tumors precisely.

Novartis first scaled RLT availability with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate).

The Indianapolis facility will supply isotopes for these treatments and future RLTs in the pipeline, pending regulatory approvals.